近日，瑞丽医美发布公告称，缪诗美学、投资者、股东及目标公司莱丽医美订立认购协议，瑞丽美学有 限公司（瑞丽医美间接非全资附属公司）以255万港元认购莱丽医美17万股，持股51.0%，比夫有限公 司以95万港元认购6.33万股，持股19.0%，缪诗美学持股30.0%。 完成后，莱丽医美将成为瑞丽医美间接非全资附属公司，财务业绩并入集团账目。莱丽医美前称"缪诗 医学美容有限公司"，尚未开展业务，计划完成后主营美容及相关服务。 (编辑：杨燕 林辰) 董事会认为，认购事项符合集团业务拓展策略，是拓展香港业务、实现协同效应的机遇，目标公司营运 及财务表现预期改善，可为集团带来潜在投资回报。 （瑞丽医美公告） ...

制售假币犯罪团伙出现在江城，经侦民警卧底假币交易现场，将该犯罪团伙"连锅端"。制售假币犯罪团 伙的覆灭，牵动着"江城杰出企业家"高天宇。 高天宇所在的新宇集团，推出"幸福颐养的养老项目"，标榜年化率高达20%的养老投资项目，用"低风 险、高回报"的诱惑、"养儿不能防老"的焦虑营销，吸引着一波波老人上钩。 新宇集团所推广的医美项目、美容贷金融产品，又吸引着怀揣明星梦的女大学生来整容，还不起美容贷 的高息后，女大学生成为女主播，又在直播间里成为"江城杰出企业家"洗钱的工具。 这是中国首部经侦题材微短剧《隐秘的ID之天价打赏》中串讲的新型经济犯罪故事。剧中故事围绕养 老公寓非法集资、直播洗钱、美容贷等真实骗局展开。短剧国服兵役专业户刘擎出演，实力派演员舒童 首次饰演反派角色，更有真警察小邱警官友情加盟。12月23日该剧甫一上线腾讯视频，便以其题材和制 作，收获了上亿的热度。 "现在年轻人都爱看微短剧，这次甄选的几个案例都是围猎年轻人的，希望通过微短剧这种新的形式， 来提高防范宣传的触达率和宣传效果。"据该微短剧的剧组方面介绍，该短剧由公安部经济犯罪侦查 局、广东省公安厅经侦总队指导，剧情皆源自真实案件改编。 美容贷 ...

当美容院和医美机构变成围猎顾客的"剧场",消费者满怀期待的变美之旅往往就沦为一场梦魇——您听 说过"医美剧本杀"吗?医美机构安插"美托儿"与顾客拼房美容,层层套路围猎消费者,所谓"价格优惠"的医 美项目转眼间变成"天价陷阱"。这类骗局危害性极大,隐蔽性极强。 套路第一环 美容院拼房设局——想变美?保守秘密 记者采访到一名求美被骗的陈女士。她经常光顾单位附近的美容院。有一天她去做美容时,为她服务的 技师佳佳有些不好意思地说,因为客人太多,房间不够用,能不能临时安排一个自己的"老客户"跟陈女士拼 房。陈女士没有多想就同意了。随后,一位衣着华丽的女士在佳佳的热情招呼下走进房间,开始了她们 的"表演"。 在接受记者采访时,消费者陈女士还原了医美"拼房剧本杀"连环套的全过程。 陈女士回忆:"这个'贵妇'说她在这儿做了一些填充项目,花了十几万元,做了好几年了,感觉这家机构的医 生比较专业,都是院长亲自给她做的,效果也挺好的。" 她说:"当时给我服务的美容师叫佳佳。她说很久都没见侯姐了,今天见到她,感觉她大变样了,她肯定做了 什么项目。佳佳一直追问侯姐,侯姐就不愿意告诉她做了什么项目。"在技师佳佳的不停央求之下,"侯 姐" ...

当天，美莱医疗还举行了胸部内窥镜&超声刀学术带教会。熊猛开展实操演示，实时展示手术流程与关键技术细节。随后，他发表《筋膜 下隆乳—假体隆乳新赛道》主题演讲，结合30余年临床经验，深度解析该联合技术的优势，二者协同应用于筋膜下隆乳，更有利于实现术后 形态自然。 据悉，四川美莱于2014年首次引进内窥镜，2015年成立数字化内窥镜隆乳技术临床应用基地，2022年2月引入首台超声刀。未来，美莱医 疗将持续以学科建设为核心，持续为广大顾客提供更优质的医美服务。 12月9日，美莱医疗学术管理部内窥镜美容专业委员会在四川美莱成立。 此举将进一步整合美莱医疗优势资源，推动技术规范与创新，推动胸部整形领域内窥镜临床应用，还为青年医师作出示范，助力胸部整 形人才建设。美莱集团总院长艾玉峰，四川美莱整形外科总院长、美莱胸部学科带头人熊猛，四川美莱整形外科技术院长、美莱胸部学科骨 干医师詹磊及青年医生出席仪式。 据介绍，该专委会将以技术研讨、人才培养、标准制定为核心，助力行业内窥镜美容技术的体系化发展。这不仅是美莱学科建设的里程 碑，更为顾客提供更安心、更有效的医美体验。 ...

Core Viewpoint - The ongoing conflict between the medical beauty platform company New Oxygen and its suppliers highlights a significant pricing power struggle in the industry, particularly regarding the pricing of the "童颜针" (youthful needle) product, which New Oxygen has drastically reduced from market prices to attract consumers [2][3][4]. Group 1: Pricing Conflict - New Oxygen has been publicly accused by suppliers, including Purity and Saint Boma, of sourcing products through unauthorized channels and has faced scrutiny over the legitimacy of its clinics [3][25]. - The core of the conflict revolves around New Oxygen's aggressive pricing strategy, which has seen the price of the "童颜针" drop from approximately 10,000 yuan to 2,999 yuan, representing a nearly 70% reduction [4][26]. - New Oxygen claims that its low pricing strategy is based on "value return," achieved through large-scale procurement and reduced marketing costs [4][26]. Group 2: Financial Performance - In the first three quarters of 2024, New Oxygen reported total revenue of 1.063 billion yuan, a year-on-year decline of 3.36%, with a net loss of 133 million yuan, a shift from a profit of 20.78 million yuan in the same period last year [14][36]. - The company's gross profit margin for the same period was 49.21%, down 13.02 percentage points year-on-year, primarily due to lower margins from offline services compared to traditional information services [16][38]. - The rapid expansion of offline beauty treatment services has led to a significant increase in revenue, with a 385.05% year-on-year growth to 427 million yuan, now accounting for 40.16% of total revenue [15][37]. Group 3: Operational Challenges - New Oxygen's shift to a heavy asset model has increased operational costs, with total operating costs reaching 540 million yuan, representing 50.8% of revenue, significantly higher than the traditional platform model [16][39]. - The company faces challenges in maintaining service quality due to a lack of a stable and experienced medical team, which is crucial for the quality of medical beauty services [39]. - Regulatory risks have increased as offline medical practices are subject to stringent oversight from multiple regulatory bodies, raising concerns about compliance and potential public relations crises [39].

更让求美者放心的是，美版超声刀的 "精准可控" 打破了传统塑形项目的局限。它配备了 DeepSee™高 解析实时影像导航系统，治疗时医生能通过屏幕清晰看到皮肤各层结构，就像拥有了 "透视眼"，可以 根据每个人的皮肤厚度、轮廓问题(如苹果肌下垂、下颌线模糊等)，灵活调整治疗的深度(1.5mm 表皮 层、3.0mm 真皮层、4.5mm 筋膜层)与能量强度。再搭配 Ulthera® 专用探头的针对性治疗，无论是想改 善表层肌肤细腻度，还是解决深层轮廓松弛，都能实现 "哪里需要调哪里" 的定制化效果，避免了传统 项目 "一刀切" 导致的不自然问题。 作为深耕医美领域多年的专业机构，VelyB 医院引入美版超声刀并非偶然 —— 从技术引进到团队培 训，每一步都围绕 "安全与效果" 展开。医院的医疗团队不仅拥有丰富的临床经验，还经过美版超声刀 品牌方的专业认证，熟悉不同肤质、不同轮廓需求的治疗技巧。针对求美者的多样化需求，医院还提供 了 100 发、300 发、600 发等不同发数的治疗方案：轻微轮廓模糊者可选少发数改善，松弛较明显者则 可通过多发数实现深层提拉，让每个人都能找到适合自己的方案。 此外，VelyB 医院的 ...

在宁波医美市场愈发追求专业与安心的当下，不少求美者都会悄悄琢磨：宁波美莱怎么样？身边人常提 的美莱医院，到底靠谱吗？毕竟选择医美，安全永远是底线，口碑更是绕不开的考量。不同于单纯罗列 优势的宣传，我们从"医研共创的专业深度"与"用户体验的真实温度"双视角切入，拆解宁波美莱的核心 竞争力，看看"美莱安全吗""美莱口碑怎么样"这些疑问，如何在实际运营中得到解答。 医研背书：资质与技术双重赋能，解答"美莱靠谱吗" 靠谱的医美机构，从来不是靠宣传造势，而是靠实打实的资质与技术说话。美莱深耕医美27年，29城40 院的连锁布局，背后是成熟的医疗管理体系与严苛的合规标准。宁波美莱作为直属机构，不仅持有完整 的《医疗机构执业许可证》，更通过质量管理体系、医学检验室双重认证，从科室设置到人员资质，每 一环都贴合国家医美规范。 2024年的两项行业荣誉，更让"美莱靠谱吗"有了硬核答案。1月，宁波美莱率先成为宁波首家薇旖美人 源化胶原"正品联盟・黑曜机构"。这一被誉为胶原界"金马奖"的认证，从医资、诊疗、服务、口碑多维 度综合评定，全宁波仅1家机构获评，足见其在抗衰领域的专业地位。同一时间，皮肤技术院长刘邦瑜 斩获华东地区"薇旖 ...

Core Viewpoint - The price war surrounding "童颜针" (youthful needle) is not only challenging the pricing system of the medical beauty industry but also testing the transformation path of the company, 新氧 (Xinyang) [1] Group 1: Price War and Market Dynamics - 新氧 has significantly reduced the price of "童颜针" from tens of thousands to 2999 yuan, aiming to gain pricing autonomy through its "奇迹童颜" series and the new "塑缇妍" product [1][8] - The conflict escalated as the manufacturer, 普丽妍, publicly named 新氧's clinics as "non-official partners," questioning their product sources and doctor qualifications [3][4] - The price reduction strategy has raised concerns about the sustainability of the medical beauty industry's profit distribution and the traditional agency model [4][5] Group 2: Transformation Challenges - 新氧's transition from a platform to a direct participant in the industry has led to conflicts with previously partnered medical institutions, resulting in a significant decline in its platform service revenue [11][12] - The company's aggressive expansion into self-operated clinics has resulted in increased costs and operational challenges, with a reported net loss of 64.3 million yuan in the third quarter [12][13] - Despite the challenges, the self-operated business is seen as a key driver for future growth, with a 304.6% year-on-year increase in medical treatment service revenue [12] Group 3: Pricing Strategy and Cost Structure - The drastic price reduction of 70% for "童颜针" is not solely based on cost but is a strategic market move to disrupt the high-price perception in the industry [5][6] - 新氧's lower pricing is attributed to its ability to bypass traditional distribution layers and its strategy of low-margin, high-volume sales [6][7] - The company claims that its pricing reflects a trend towards "value return" in medical beauty consumption, with a 27.1% increase in consumer visits but a 30.9% decrease in average spending [7] Group 4: Regulatory and Compliance Issues - 新氧 has faced multiple regulatory challenges, including fines for non-compliance with national standards and advertising laws [13][14] - The company acknowledges the importance of addressing consumer complaints and emphasizes that its low-cost model does not compromise regulatory compliance [14]

Core Viewpoint - The ongoing price war surrounding "童颜针" (youthful needle) is not only challenging the pricing system of the medical beauty industry but also represents a critical transformation path for the company, 新氧 (So-Young) [2][14]. Group 1: Price War and Market Dynamics - 新氧 has significantly reduced the price of "童颜针" from over 10,000 RMB to 2,999 RMB, aiming to gain control over pricing autonomy [2][10]. - The company faces accusations from suppliers like 普丽妍, which has labeled many of 新氧's clinics as "non-official partners," questioning the legitimacy of their product sources and medical qualifications [3][4]. - The price reduction strategy is seen as a challenge to the traditional profit distribution model in the medical beauty industry, where high prices were previously justified by perceived quality [6][7]. Group 2: Transformation Challenges - 新氧 is transitioning from a platform-based model to a direct participant in the medical beauty industry by establishing its own clinics, which has led to conflicts with previously partnered medical institutions [14][15]. - The company's revenue from information and reservation services has declined significantly, with a 34.5% year-on-year drop in the third quarter [14]. - Despite the aggressive expansion into self-operated clinics, 新氧 has reported continuous losses, with a net loss of 64.8 million RMB in the third quarter of 2025 [15][16]. Group 3: Financial Performance and Cost Structure - 新氧's aesthetic treatment services revenue surged by 304.6% year-on-year to 1.84 billion RMB in the third quarter, becoming the largest revenue source [17]. - The gross profit margin for 新氧's medical aesthetic services was reported at only 24.25% in the second quarter of 2025, indicating a significant deviation from industry standards [8][9]. - The company is focusing on cost optimization through strategies like scale procurement and supply chain integration to improve profitability [17]. Group 4: Regulatory and Compliance Issues - 新氧 has faced multiple complaints regarding service quality and compliance, with 876 complaints recorded on consumer platforms, including issues related to false advertising and operational violations [17][19]. - The company has been penalized for non-compliance with national standards, highlighting the regulatory risks associated with its rapid expansion [17][18]. - 新氧 emphasizes that its low pricing strategy does not compromise regulatory compliance and is committed to addressing consumer feedback seriously [19].

南京东南美容医院有限公司（下称 "东南美容医院"）因网络宣传推广合作纠纷，将网红"虫虫 chonny"诉至南京市建邺区人民法院，要求其返还合同款 45.69 万元及逾期利息、律师费等，涉案金额 合计暂达 48.3379 万元。令人意外的是，医美公司在维权过程中发现，该网红在签订合作协议前已移民 国外，这为款项追回增添了变数。 东南美容医院与"虫虫 chonny"交涉的微信聊天截图显示，"虫虫 chonny"对医美公司统计的引流人数有 异议，她认为应该算在引流人数内的人员，医美公司没有算入，同时"虫虫 chonny"对自己在东南美容 医院做的手术不满意。 目前，南京市建邺区人民法院已受理该案，相关审理工作正在推进中。 浙江铁券律师事务所高级合伙人张永辉律师认为，根据《民法典》第四百六十五条，依法成立的合同受 法律保护且仅对当事人具有法律约束力。南京东南美容医院与"虫虫 chonny"签订的《独家网络宣传推 广合作合同》，若双方具备相应民事行为能力、意思表示真实且不违反法律强制性规定，应认定为有效 合同。尽管"虫虫 chonny"在签订合同时隐瞒已移民事实，但合同本身不存在法定无效情形，其效力不 受影响。不过，若 ...